I dette fase 3 kliniske forsøg udviste palifermin behandlede patienter signifikante fordele i patient rapporteret resutat af mund - og svælg- ømhed og dets indvirken på at synke, drikke, spise og tale.
In this Phase 3 clinical study, palifermin treated patients demonstrated significant benefits in patient-reported outcomes of mouth and throat soreness and its impact on swallowing, drinking, eating and talking.